Biomoneta Research launches indoor air-purification and microbial decontamination device Avata Air

Bengaluru-based Biomoneta Research has announced the launch of Avata Air, an indoor air-purification and microbial decontamination device, in collaboration with Panasonic.

The product is now available through Panasonic’s MirAIe Lifestyle platform, marking Biomoneta’s entry into the Indian consumer air-care market. Unlike conventional air purifiers that primarily focus on dust, smoke and particulate matter, Avata Air has been designed to address both common airborne pollutants and invisible biological contaminants present in indoor environments.

The company’s medical-grade product, Avata Rx, received clearance from the United States Food and Drug Administration as a Class II medical device. Avata Air is a separate consumer product, but incorporates the same underlying ZeBox technology used in the US FDA-cleared Avata Rx platform.

“Avata Air represents an important milestone in Biomoneta’s journey,” said Arindam Ghatak, Co-founder and Chief Executive Officer of Biomoneta Research. “For more than a decade, we have worked to understand how airborne microorganisms can be captured and eliminated safely in occupied spaces. Through this collaboration with Panasonic, we can now bring the same core technology developed for demanding healthcare environments into Indian homes.”